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Objectives: To monitor antiviral drug resistance among seasonal influenza
viruses isolated in Korea during the 2008e2009 influenza season, we examined
influenza isolates collected through Korea Influenza Surveillance Scheme for
antiviral drug susceptibility.
Methods: For genetic analysis of antiviral drug resistance, the matrix (M2) and
neuraminidase (NA) genes of each isolate were amplified by reverse tran-
scription-polymerase chain reaction and followed by nucleotide sequencing.
For phylogenetic analyses, the sequences of hemagglutinin (HA) and NA genes
of each isolate were aligned using multiple alignment program. For phenotypic
analysis of antiviral drug resistance, drug susceptibilities against M2 inhibitor
(amantadine) and NA inhibitors (oseltavimir and zanamivir) were determined
by virus yield reduction assay and fluorometric NA inhibition assay, respec-
tively.
Results: In Korea, the resistant influenza viruses against oseltamivir were first
detected in sealsonal influenza A(H1N1) viruses on Week 48 of 2008. Since then,
the number of oseltamivir-resistant A(H1N1) viruses was continuously increased
and had reached the highest peak on Week 52 of 2008. 533 (99.8%) of 534 A(H1N1)
viruses were resistant to oseltamivir and all of them harbored the H275Y muta-
tion in the NA gene during the 2008e2009 season. The oseltamivir resistance
identified by sequencing was confirmed by NA inhibition assay. Genetic analysis
based on HA gene of the resistant A(H1N1) viruses revealed that the viruses were
identified as A/Brisbane/10/2007-like strain which was vaccine strain for the
2008e2009 season.
Conclusions: The oseltamivir-resistant A(H1N1) viruses were first emerged in
Europe in November 2007 and then circulated globally. One year later, the
oseltamivir-resistant A(H1N1) viruses were first detected in Korea in November
2008 and continued circulating until the Week 7 of 2009 during the 2008e2009ibuted under the terms of the Creative Commons Attribution Non-Commercial License
y-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in
is properly cited.
ributed equally to this study.
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Oseltamivir-resistant seasonal A (H1N1) virus in Korea 179season. Considering the pandemic preparedness, it should be continued to
monitor the emergence and the characterization of antiviral drug resistant
influenza viruses.1. Introduction
Influenza spreads around the world in seasonal
epidemics, resulting in the deaths of 250,000e500,000
people every year [1]. Especially since April 2009,
18,449 deaths from the laboratory-confirmed pandemic
(H1N1) 2009 were reported from 214 countries world-
wide (as of August 1, 2010) [2]. Vaccination and anti-
viral treatments are essential for the prevention and
control of influenza infection.
Recently, the oseltamivir-resistant seasonal influenza
A(H1N1) virus was first reported to the World Health
Organization by Norway in late January 2008 [3].
However, the earliest detection of oseltamivir-resistant
seasonal influenza A(H1N1) virus was in France and
the United Kingdom on Week 46 of 2007 and in Norway
on Week 47 of 2007 [4], and then an increased number
of oseltamivir-resistant seasonal influenza A (H1N1)
viruses has been spread worldwide [5e9]. According to
the World Health Organization (WHO) report (as of
March 18, 2009) [10], the prevalence of oseltamivir
resistance in seasonal influenza A (H1N1) virus was
95% worldwide. All these oseltamivir-resistant isolates
have the same mutation in the neuraminidase gene
(H275Y in N1 numbering), conferring resistance to
oseltamivir but not to zanamivir.
The predominant influenza subtype circulating in
Korea during 2008e2009 season was seasonal influenza
A (H1N1). To determine whether the oseltamivir-resistant
viruses have spread to Korea, we examined seasonal
influenza A (H1N1) isolated in Korea from Week 36 of
2008 to Week 35 of 2009 for antiviral susceptibility.
In this study, we tested 534 (18.5%, 534/2,880)
influenza A (H1N1) viruses among 2880 influenza A
(H1N1) viruses isolated throughout the country by the
Korean Influenza Surveillance Scheme (KISS) during
the 2008e2009 influenza season. For genetic analysis of
M2 gene, we analyzed the amino acid substitutions at
positions 26, 27, 30, 31, or 34 within the transmembrane
domain of the M2 protein, known to confer resistance to
amantadine [11]. For genetic analysis of NA gene, we
also analyzed influenza A (H1N1) virus for amino acid
substitutions at positions 119, 136, 223, 275, 293, and
295 of the NA gene (N1 numbering), known to confer
resistance to neuraminidase inhibitor drugs [12,13]. We
also phylogenetically analyzed both HA1 and NA
sequences in the influenza A (H1N1) viruses.
Here we described the high rate of oseltamivir-
resistant influenza A (H1N1) viruses identified from
influenza surveillance in Korea during the 2008e2009influenza season and the circulation of these viruses
globally based on the sequence data.2. Materials and Methods
2.1. Viruses
Influenza isolates obtained by KISS from Week 36 of
2008 to Week 35 of 2009 were used in this study.
Viruses were randomly selected by region and date, and
534 A (H1N1) viruses were tested for genotype and
phenotype resistant to amantadine and neuraminidase
inhibitors (oseltamivir and zanamivir).
Viruses were propagated in Madin-Darby Canine
Kidney (MDCK) cells in Dulbecco’s modified essential
medium (DMEM) supplemented with 5% fetal bovine
serum at 35C and with 5% CO2. Viral stocks were
stored at e70C.
2.2. Extraction of viral RNA
Viral RNA was extracted from 140 mL of virus
culture using a total RNA isolation kit and a QuickGene-
810 instrument (Fujifilm, Tokyo, Japan) according to the
manufacturer’s instructions. RNA was eluted in 50 mL
of the elution buffer provided in the kit and either used
directly in reverse transcription polymerase chain reac-
tion (RT-PCR) or stored at e70C.
2.3. RT-PCR for the M2, NA, and HA genes
Detailed methods of RT-PCR for the M2, NA, and
HA genes are described in the Supplementary Methods
online.
2.4. Sequence analysis
The PCR products were purified for sequencing by
using PCR product purification kit (Qiagen, Hilden,
Germany). Both strands were sequenced by an auto-
mated method with fluorescent dideoxy-chain termina-
tors (Applied Biosystems, Foster City, USA). At least
two corresponding electropherograms for the M2, NA,
and HA regions were analyzed. The sequences were
aligned with the MegAlign program (DNASTAR Inc.
Software, Madison, WI, USA). We analyzed the estab-
lished M2 inhibitor resistance markers (26, 27, 30, 31, or
34 of M2 protein) and NA inhibitor resistance markers
(119, 136, 223, 275, 293, and 295 of the NA protein in
N1 numbering) in influenza viruses. We also phyloge-
netically analyzed the HA1 and NA coding regions in
the influenza A (H1N1) virus by using MEGA with the
neighbor-joining method [14]. The nucleotide sequences
180 W.-Y. Choi, et alof the Korean isolates used in this study were compared
with those of the WHO recommended vaccine strains
and other reference strains from GenBank (National
Center for Biotechnology Information, NCBI).
2.5. Neuraminidase inhibition assay
Fluorescence-based neuraminidase inhibition (NI)
assay according to the WHO Collaborating Centre for
Reference and Research on Influenza manual was con-
ducted using 405 influenza A (H1N1) viruses isolated in
Korea during the 2008e2009 season. A detailed method
of the neuraminidase inhibition assay is described in the
Supplementary Methods online.3. Results
3.1. Seasonal surveillance
Influenza viruses were obtained from KISS during
the 2008e2009 season from influenza-like illness
patients in seven cities and nine provinces, representing
all regions of South Korea.
Overall influenza activity in Korea was prevailed by
A (H1N1) and A (H3N2) viruses during the 2008e2009
season compared with B virus during the 2007e2008
season. A total of 5025 influenza viruses were isolated
and 3214 (64.0%), 1748 (34.8%), and 63 (1.3%) were
identified as influenza A (H1N1), A (H3N2), and
influenza B viruses, respectively, during the 2008e2009
season (Figure 1). The first virus in this season was
isolated on Week 37 of 2008 and the strain was influ-
enza A (H3N2) virus and then one more virus of A
(H3N2) was isolated on Week 43. Influenza A (H1N1)
virus was first observed on Week 48 of 2008, and it
dramatically increased until Week 52 of 2008, and then
decreased to Week 7 of 2009. Isolation of the virusesFigure 1. Weekly distribution of influenza virus isolation during
viruses sequentially became major isolates at initial and later times,
of virus isolation of A (H1N1), A (H3N2), and B viruses, respectiformed a peak on Week 52 of 2008. A (H3N2) viruses
were rapidly increased from Week 12 and formed a peak
at Week 15 of 2009. In the case of the B virus, it was
first detected after Week 2 of 2009 and then several
isolates were detected each week. Two major peaks of
positive rate of virus isolation were observed in this
season, which were directly correlated with the largest
number of isolates of A (H1N1) and A (H3N2) viruses,
respectively.
3.2. Antiviral resistance
3.2.1. Resistance of NA inhibitors
For genetic analysis of NA gene, nucleotide
sequences of the NA gene were determined for the
influenza A isolates. At the end of November 2008
(Week 48), an unusual high proportion (15/16) of
oseltamivir-resistant strains was detected in A (H1N1)
viruses that had an amino-acid change of histidine to
tyrosine at the 275th position (N1 numbering) in the NA
gene. All the resistant isolates (n Z 533) possessed the
H275Y mutation in the NA gene. Overall, a resistance
profile for 533 of the 534 A (H1N1) viruses (99.8%)
was obtained through genotypic analysis of NA genes
(Table 1). Influenza A (H1N1) viruses (n Z 405) were
also investigated by phenotypic analysis using
fluorescence-based neuraminidase inhibitor (NI) assay.
Among these, all the H275Y resistant isolates (nZ 404)
were resistant to oseltamivir (mean IC50: 643.4), while
still susceptible to zanamivir (mean IC50: 0.53). The
data from NI assay correlated 100% for virus genotypes
and was identified by sequencing.
3.2.2. Amantadine resistance
Influenza A viruses resistance to amantadine were
analyzed by the sequencing of M2 region. We randomlythe 20082009 season. Influenza A (H1N1) and A (H3N2)
respectively. Bars of blue, orange, and green represent number
vely. The red line represents positive rate of virus isolation.
Table 1. Weekly distribution of oseltamivir-resistant
A/H1N1 viruses
Year Week
A (H1N1)
No. of resistant/tested Resistance rate (%)
2008 48 15/16 93.8
49 28/28 100
50 56/56 100
51 86/86 100
52 143/143 100
2009 1 87/87 100
2 65/65 100
3 29/29 100
4 15/15 100
5 4/4 100
6 3/3 100
7 2/2 100
Total 533/534 99.8%
Oseltamivir-resistant seasonal A (H1N1) virus in Korea 181selected 572 (17.8%) of the 3214 influenza A(H1N1)
and 287 (16.4%) of the 1748 influenza A(H3N2) viruses
during the 2008e2009 season. The M2 genes of 859
influenza A viruses were amplified by RT-PCR and
followed by sequencing. The rate of resistance of A
(H1N1) and A (H3N2) during this period was 2.1% (12/
572) and 99.3% (285/287), respectively (Table 2). Our
data showed that all resistant viruses contained the S31
N substitution in the M2 protein known to confer
amantadine resistance [10]. Other drug-resistant M2
mutations at positions 26, 27, 30, and 34 were not
detected in these resistant isolates. The amantadine
resistance identified by sequencing was confirmed by
virus yield reduction assay. The data from the biologic
assay correlated 100% for virus genotypes identified by
sequencing (data not shown).
3.3. Phylogenetic analysis of HA and NA genes
A total of 523 HA (HA1 subunit 326 amino-acids)
sequences (16.3%, 523/3214) and 532 NA (full-length
470 amino-acids) sequences (16.6%, 532/3214) of
influenza A (H1N1) during the 20082009 season were
analyzed to generate phylogenetic trees. The first A
(H1N1) isolate during the 2008e2009 season was
oseltamivir-sensitive virus and clustered in clade 2C,
represented by A/Hong Kong/2652/2006, while most ofTable 2. Frequency of antiviral drug resistance of influenza A
Type
A
Oseltamivir
No. of
resistant/tested
Resistance
rate (%)
No. o
resistant/t
A (H1N1) 533/534 99.8 0/534
A (H3N2) 0/295 0.0 0/295the A (H1N1) viruses during the 20082009 season
were oseltamivir-resistant viruses and belonged to clade
2B, represented by A/Brisbane/10/2007, which is the
2008e2009 influenza vaccine strain (Figure 2). The
representative amino-acid changes in HA and NA genes
were denoted on the phylogenetic tree (Figure 2).
A/Brisbane/59/2007-like viruses (clade 2B) commonly
had D35 N, R188 K, and E273 K in HA1 coding regions
(H3 numbering), and H45 N, K78E, G249 K, T287I, and
K329E in NA coding regions (N1 numbering) when
compared with the two genes of A/New Caledonia/20/
1999 vaccine strain from the 20002001 to the
20062007 seasons. Most of the isolates from the
2007e2008 season didn’t have the A189 T mutation in
HA1 coding regions, while most isolates from the
2008e2009 season possessed an A189 T mutation in the
HA1 coding regions (Figure 2A). Unlike the HA1
coding region, the difference in amino-acid change for
each season was not observed in the NA coding region.
All oseltamivir resistant viruses since the 20072008
season had a D354 G mutation as well as H275Y in NA
coding regions compared with those of A/Brisbane/59/
2007 (Figure 2B). In Korea, most A/Brisbane/59/2007-
like viruses isolated from the 20082009 season were
distinctly grouped on phylogenetic tree, which was
characterized by two amino-acid changes, S141 N and
G185A, in the HA genes (Figure 2A, triangle). The
mutations in the HA genes were corresponded to four
unique nucleotide changes: A123 G, T243A, C852 T,
and A1080 G in NA genes (numbering from start codon
of NA gene). This is depicted in Figure 2B (asterisk).
Besides S141 N and G185A in the HA1 coding region,
only a few isolates had S141 K, N183S/G185S, or G185
V/H192R variations. Of isolates containing S141 N and
G185A were in the HA1 coding region, some isolates
additionally harbored I184 M in the HA1 coding region
and G41R or T467I in the NA coding region.4. Discussion
To monitor the drug resistance of influenza A viruses,
we performed genetic and phenotypic analyses of the
NA and M2 genes of Korean isolates during the
2008e2009 season (Table 2). For oseltamivir and
zanamivir resistance, a total of 829 influenza A virusesviruses during the 2008e2009 season
ntiviral drug
Zanamivir Amantadine
f
ested
Resistance
rate (%)
No. of
resistant/tested
Resistance
rate (%)
0.0 12/572 2.1
0.0 285/287 99.3
Figure 2. Phylogenetic tree analysis of the HA1 coding region of the (A) hemagglutinin; and (B) neuraminidase coding region of
human influenza A (H1N1) viruses isolated in Korea during the 2008e2009 season. Phylogenetic tree analysis of the HA1 and NA
coding regions from strains isolated in Korea, rooted with A/New Caledonia/20/1999. Oseltamivir-resistant strains are denoted in
bold.
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184 W.-Y. Choi, et al[534 A (H1N1) and 295 A (H3N2)] were tested. In
particular, oseltamivir-resistant A (H1N1) viruses have
been found through the KISS at the end of November
2008 and this is the first case of oseltamivir-resistant A
(H1N1) in Korea. Until the 2007e2008 season, seasonal
influenza A (H1N1), A (H3N2), and B viruses circu-
lating in Korea remained sensitive to NA inhibitors
(oseltamivir and zanamivir). Overall, 533 oseltamivir-
resistant A (H1N1) viruses (99.8%, 533/534) were
detected during the 2008e2009 season and no
oseltamivir-resistant A (H3N2) viruses (0.0%, 0/295)
were observed. There were no isolates resistant to
zanamivir among 829 influenza A viruses (0.0%, 0/829).
For amantadine resistance, a total of 859 influenza A
viruses [572 A (H1N1) and 287 A (H3N2)] were tested.
The rate of resistance against amantadine of A (H1N1)
and A (H3N2) was 2.1% (12/572) and 99.3% (285/287),
respectively. The frequency of amantadine resistant A
(H1N1) viruses (2.1%) was much lower than that of the
previous season (97.8%), whereas that of amantadine
resistant A(H3N2) viruses (99.3%) had the same high
level seen in the previous season (100%). Based on the
antiviral resistance rates of influenza A (H1N1) and A
(H3N2) viruses each season, we assume that resistant
viruses are circulating independently of the drug use,
and the resistance rate of the isolates might depend on
the degree of the transmissibility of the circulating
resistant viruses, as reported previously [15].
To investigate whether these oseltamivir resistant
viruses might be transmitted from abroad, we examined
travelers who suspected influenza-like illness coming
through Incheon International Airport in South Korea.
Of 15 specimens collected at the airport during January
to March 2009, six A (H1N1) and three A (H3N2)
viruses were isolated. The A (H1N1) viruses were iso-
lated from travelers who visited Hong Kong, Kazakh-
stan, the Philippines, and Thailand. Through a sequence
analysis of the HA and NA genes, all A (H1N1) viruses
were identified as the oseltamivir resistant viruses and
all A (H3N2) viruses were not. Furthermore, the
sequences of these A (H1N1) viruses were grouped
together with most of Korean A (H1N1) isolates
(Figure 2, arrows). It revealed that the resistant A
(H1N1) viruses could be introduced into Korea by
travelers coming from these foreign countries.
Based on the phylogenetic analysis of the HA and
NA genes, this emergence of oseltamivir-resistant
influenza A (H1N1) virus in Korea coincided with the
dominant circulation of this virus during the 2007e2008
season in Europe [4]. Phylogenetic analysis of the HA1
coding region of Korean isolates during the 2008e2009
season showed most of Korean A (H1N1) viruses
belonged to clade 2B, represented by A/Brisbane/10/
2007, which is the 2008e2009 influenza vaccine strain
(Figure 2A). Most of Korean isolates from the
2008e2009 season possessed an A189 T mutation in the
HA1 coding regions (Figure 2A), as reported in Japan[5]. Phylogenetic analysis of the NA coding region of
the Korean isolates during the 2008e2009 season
showed that the viruses fall into clade 2B. They clus-
tered together with A/Norway/1736/2007, which were
isolated in Norway in November 2007 (Figure 2B). It
also showed that all of the oseltamivir resistant viruses
since the 20072008 season containing the Korean
resistant viruses and A/Norway/1736/2007 possessed
the D354 G mutation as well as the H275Y mutation in
NA genes compared with those of A/Brisbane/59/2007
(Figure 2B) [4,5]. This suggests that the oseltamivir
resistant viruses first emerged in Europe in November
2007 and circulated globally to many countries,
including the United States, Canada, South Africa,
Australia, and Japan, and then would spread to Korea
in November 2008 [4e9]. These oseltamivir-resistant
viruses are easily transmissible and circulate indepen-
dently of drug use. It suggests that the genetic variations
of the HA and NA genes may contribute to their overall
fitness and transmissibility.
Here, our data provide the information on the
adequate use of antiviral drugs in a rapid manner for
influenza treatment through antiviral resistance moni-
toring. Thorough monitoring of antiviral resistance in
influenza viruses is therefore an essential part of influ-
enza virus surveillance and is needed to track the
emergence and worldwide spread of drug-resistant
viruses.
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